← Leaderboards
Rachel Ruckdeschel Smith
Capricor, Inc.
$5,323,489
Attributed
$6,820,123
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3M · FY2009–15$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
Funding mix
By agency
NIH$6,820,123 · 2
By mechanism
R44$3,826,855 · 1
RC3$2,993,268 · 1
Top collaborators
- Linda Marban1 shared
Others in their field
Top investigators on “United States”
- Leonard Freedman · Leidos Biomedical Research, Inc.$818,172,357
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Lawrence Corey · Fred Hutchinson Cancer Center$638,373,375
- David Heimbrook · Leidos Biomedical Research, Inc.$632,657,800
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
Research focus
United StatesAffectMyocardial InfarctionSeriesMarketingCardiacLeftCommercializationLicensingSafetyCardiovascular DiseasesCause Of DeathMyocardiumManufacturing ProcessDesignCellsClinical TrialsAutologousInjuryAnimal ModelAllogenicInfarctionNatural RegenerationEnsure
Grant awards (7)
Safety of Allogeneic Cardiosphere-Derived Cells for Dilated Cardiomyopathy$880,760
R44 · FY2015 · HL · contact PI
Safety of Allogeneic Cardiosphere-Derived Cells for Dilated Cardiomyopathy$998,765
R44 · FY2014 · HL · contact PI
Safety of Allogeneic Cardiosphere-Derived Cells for Acute Myocardial Infarction$999,912
R44 · FY2013 · HL · contact PI
Characterization and Potency of Optimized Cardiosphere-derived Stem Cell Method$425,410
R44 · FY2012 · HL · contact PI
Characterization and Potency of Optimized Cardiosphere-derived Stem Cell Method$397,217
R44 · FY2011 · HL · contact PI
Safety and Efficacy of Allogeneic Cardiosphere-derived Stem Cells After MI$2,993,268
RC3 · FY2010 · HL · contact PI
Characterization and Potency of Optimized Cardiosphere-derived Stem Cell Method$124,791
R44 · FY2009 · HL · contact PI